Takeda’s Entyvio Faces PML Hurdle At Advisory Committee, Thanks To Tysabri
This article was originally published in The Pink Sheet Daily
Entyvio’s clinical trials found no cases of progressive multifocal leukoencephalopathy, but FDA remains concerned because the product’s mechanism of action is similar to Tysabri, which is associated with PML.
You may also be interested in...
Sotagliflozin Hail Mary? Lexicon Seeks Opportunity For Formal Hearing On FDA Intent To Deny Approval
After complete response letter, Lexicon triggers rarely used mechanism for formal hearing, prompting US FDA to publicly list its problems with the proposed type 1 diabetes drug, for which Sanofi had originally sought approval.
As agency implements testing program for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.